Alida Barry, RAC

Ms. Barry is vice president, head of regulatory affairs at Autobahn Therapeutics, Inc. 

Ms. Barry is a strategic, innovative and accomplished regulatory leader who brings more than 15 years of experience in US, EU and global drug development to Autobahn. Ms. Barry has successfully advanced early and late-stage development programs across a diverse range of therapeutic areas, including CNS, ophthalmology, anti-infectives, immunology, hematology and rare/orphan diseases from pre-IND through approval and commercial launch. Prior to joining Autobahn, Ms. Barry held progressive leadership roles at pharmaceutical companies ranging from small to large multinational organizations, including Acadia Pharmaceuticals Inc., Shire/Takeda, Cubist/Merck, and Genzyme/Sanofi. Ms. Barry spearheaded multiple successful global approvals, product launches, and label expansion (Xiidra^®, NUPLAZID^®, Cubicin^®), including leading successful INDs/CTAs. She prepared teams for regulatory interactions, including pre-IND, End-of-Phase, Scientific Advice, pre-NDA, and defense of marketing applications. She has a proven track record of successful labeling negotiations and served as regulatory lead for corporate advertising and promotional materials. Ms. Barry has also played a central role in securing Orphan Designation, Fast Track Designation, and Breakthrough Therapy Designation for several products. Ms. Barry holds a Bachelor of Science degree from Gordon College and Regulatory Affairs Certification from Regulatory Affairs Professional Society.